Search Results
Search for other papers by R A Stein in
Google Scholar
PubMed
Search for other papers by D P McDonnell in
Google Scholar
PubMed
identify key obstacles and questions that must be resolved if ERRα is to be utilized as a therapeutic target in breast cancer. The estrogen receptor-signaling pathway In the absence of hormone, estrogen receptor (ER) resides in either
Search for other papers by A Coopes in
Google Scholar
PubMed
Search for other papers by C E Henry in
Google Scholar
PubMed
Search for other papers by E Llamosas in
Google Scholar
PubMed
Search for other papers by C E Ford in
Google Scholar
PubMed
ovarian tumours resemble clear cell lesions of the endometrium, suggesting common therapeutic targets ( Fadare et al . 2013 , Levine & The Cancer Genome Atlas Research Network 2013 , Hoang et al . 2014 ). By contrast, while endometrioid endometrial
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Goswin Y Meyer-Rochow in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Nicole E Jackson in
Google Scholar
PubMed
Search for other papers by John V Conaglen in
Google Scholar
PubMed
Search for other papers by Denis E Whittle in
Google Scholar
PubMed
Search for other papers by Muthusamy Kunnimalaiyaan in
Google Scholar
PubMed
Search for other papers by Herbert Chen in
Google Scholar
PubMed
Search for other papers by Gunnar Westin in
Google Scholar
PubMed
Search for other papers by Johanna Sandgren in
Google Scholar
PubMed
Search for other papers by Peter Stålberg in
Google Scholar
PubMed
Search for other papers by Elham Khanafshar in
Google Scholar
PubMed
Search for other papers by Daniel Shibru in
Google Scholar
PubMed
Search for other papers by Quan-Yang Duh in
Google Scholar
PubMed
Search for other papers by Orlo H Clark in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Anthony J Gill in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Rory Clifton-Bligh in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Bruce G Robinson in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Diana E Benn in
Google Scholar
PubMed
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Cancer Genetics, Endocrine and Oncology Surgery, Endocrinology, Anatomical Pathology, Faculty of Medicine, Surgery, Endocrinology, Endocrine Surgery Research Laboratories, Department of Surgical Sciences, Departments of Surgery and Pathology, Endocrine Oncology Section, Hormones and Cancer Group, Kolling Institute of Medical Research, Departments of
Search for other papers by Stan B Sidhu in
Google Scholar
PubMed
chemotherapy or radiotherapy with a poor overall survival of 50% at 5 years ( Adler et al . 2008 ). The identification of reliable diagnostic and prognostic markers and the development of effective molecular therapeutic targets for the treatment of malignant
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Search for other papers by Miguel A Zaballos in
Google Scholar
PubMed
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Search for other papers by Adrián Acuña-Ruiz in
Google Scholar
PubMed
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander, Spain
Search for other papers by Marta Morante in
Google Scholar
PubMed
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander, Spain
Search for other papers by Piero Crespo in
Google Scholar
PubMed
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Search for other papers by Pilar Santisteban in
Google Scholar
PubMed
( Herrero et al. 2015 ). This illustrates how targeting a protein–protein interaction can yield therapeutic effects. The RAS/ERK pathway offers multiple potential therapeutic targets. We will next describe the main RAS GAPs and GEFs, the scaffold
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Laura Gerard in
Google Scholar
PubMed
Search for other papers by Céline Patte in
Google Scholar
PubMed
Search for other papers by Laurence Chardon in
Google Scholar
PubMed
Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Léa Payen in
Google Scholar
PubMed
Search for other papers by Marion Allio in
Google Scholar
PubMed
Search for other papers by Claire Marx in
Google Scholar
PubMed
Search for other papers by Hugo Clermidy in
Google Scholar
PubMed
Search for other papers by Alice Durand in
Google Scholar
PubMed
Search for other papers by Patrick Mehlen in
Google Scholar
PubMed
Search for other papers by Julien Bollard in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Colette Roche in
Google Scholar
PubMed
Search for other papers by Benjamin Gibert in
Google Scholar
PubMed
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
). NRP2 could thus represent a promising therapeutic target in NENs. An antibody directed against a part of the transmembrane domain (b1b2) of NRP2 has been developed and inhibits tumour growth and metastasis in pancreatic ductal adenocarcinoma via
Search for other papers by Hung-Ming Lam in
Google Scholar
PubMed
Search for other papers by Bin Ouyang in
Google Scholar
PubMed
Search for other papers by Jing Chen in
Google Scholar
PubMed
Search for other papers by Jun Ying in
Google Scholar
PubMed
Search for other papers by Jiang Wang in
Google Scholar
PubMed
Search for other papers by Chin-Lee Wu in
Google Scholar
PubMed
Search for other papers by Li Jia in
Google Scholar
PubMed
Department of Environmental Health, Department of Pathology and Laboratory Medicine, Department of Pathology, Department of Medicine, Center for Environmental Genetics, Department of Urology, Cincinnati Veterans Affairs Medical Center, Cincinnati Cancer Center, University of Cincinnati Medical Center, Room 128 Kettering Complex, Cincinnati, Ohio 45267‐0056, USA
Search for other papers by Mario Medvedovic in
Google Scholar
PubMed
Search for other papers by Robert L Vessella in
Google Scholar
PubMed
Department of Environmental Health, Department of Pathology and Laboratory Medicine, Department of Pathology, Department of Medicine, Center for Environmental Genetics, Department of Urology, Cincinnati Veterans Affairs Medical Center, Cincinnati Cancer Center, University of Cincinnati Medical Center, Room 128 Kettering Complex, Cincinnati, Ohio 45267‐0056, USA
Department of Environmental Health, Department of Pathology and Laboratory Medicine, Department of Pathology, Department of Medicine, Center for Environmental Genetics, Department of Urology, Cincinnati Veterans Affairs Medical Center, Cincinnati Cancer Center, University of Cincinnati Medical Center, Room 128 Kettering Complex, Cincinnati, Ohio 45267‐0056, USA
Department of Environmental Health, Department of Pathology and Laboratory Medicine, Department of Pathology, Department of Medicine, Center for Environmental Genetics, Department of Urology, Cincinnati Veterans Affairs Medical Center, Cincinnati Cancer Center, University of Cincinnati Medical Center, Room 128 Kettering Complex, Cincinnati, Ohio 45267‐0056, USA
Search for other papers by Shuk-Mei Ho in
Google Scholar
PubMed
PC We reasoned that GPR30 in CRPC metastases needs to be expressed at significant levels before we can consider it as a new therapeutic target for CRPC. Hence, we used IHC to assess the level of GPR30 expression in specimens obtained from two cohorts
Search for other papers by G Capurso in
Google Scholar
PubMed
Search for other papers by S Lattimore in
Google Scholar
PubMed
Search for other papers by T Crnogorac-Jurcevic in
Google Scholar
PubMed
Search for other papers by F Panzuto in
Google Scholar
PubMed
Search for other papers by M Milione in
Google Scholar
PubMed
Search for other papers by V Bhakta in
Google Scholar
PubMed
Search for other papers by N Campanini in
Google Scholar
PubMed
Search for other papers by S M Swift in
Google Scholar
PubMed
Search for other papers by C Bordi in
Google Scholar
PubMed
Search for other papers by G Delle Fave in
Google Scholar
PubMed
Search for other papers by N R Lemoine in
Google Scholar
PubMed
, and offers a potential novel therapeutic target for PETs. LCK is an src-like non-receptor protein tyrosine kinase, expressed mainly in T lymphocytes and thymocytes ( Anderson et al . 1994 ). LCK is also aberrantly expressed in different cancer types
Search for other papers by Deborah J Marsh in
Google Scholar
PubMed
. Endocrine-Related Cancer 22 T35 – T54 . ( doi:10.1530/ERC-14-0516 ). Shen M Schmitt S Buac D Dou QP 2013 Targeting the ubiquitin-proteasome system for cancer therapy . Expert Opinion on Therapeutic Targets 17 1091 – 1108 . ( doi:10
Search for other papers by Meenu Jain in
Google Scholar
PubMed
Search for other papers by Lisa Zhang in
Google Scholar
PubMed
Search for other papers by Mei He in
Google Scholar
PubMed
Search for other papers by Ya-Qin Zhang in
Google Scholar
PubMed
Search for other papers by Min Shen in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
Given that TOP2A was highly expressed in ACC samples, we evaluated its potential as a therapeutic target for ACC in vitro . Eleven of 14 TOP2A inhibitors had an antiproliferative effect in the NCI-H295R ACC cell line, five of the TOP2A inhibitors
Search for other papers by Stephen Hiscox in
Google Scholar
PubMed
Search for other papers by L Morgan in
Google Scholar
PubMed
Search for other papers by Tim Green in
Google Scholar
PubMed
Search for other papers by Robert I Nicholson in
Google Scholar
PubMed
et al. 2005 ). In this paper, we discuss the consequences of increased Src activity for the development of an aggressive, invasive cell phenotype and demonstrate its potential as a therapeutic target for anti-invasive therapies. Furthermore, our